Henry Schein (HSIC)
(Delayed Data from NSDQ)
$70.37 USD
+0.14 (0.20%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $70.37 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.37 USD
+0.14 (0.20%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $70.37 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Zacks News
Henry Schein's (HSIC) Q4 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
Strength in Henry Schein's (HSIC) global Medical and Technology and Value-added Services businesses in Q4 is encouraging.
Can Dental Growth Drive Henry Schein's (HSIC) Q4 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is well placed to gain from digitalization in the global dental market.
Henry Schein (HSIC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein Animal Health Spin-Off Approaches, Costs Mount (revised)
by Zacks Equity Research
Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.
Near-Term Outlook for Dental Supplies Industry Looks Bright
by Zacks Equity Research
The wave of digital transformation is shaping the future of dental supply companies.
Henry Schein Animal Health Spin-Off Approaches, Cost Mounts
by Zacks Equity Research
Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.
Henry Schein (HSIC) Up 3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in Store for Patterson Companies' (PDCO) Q2 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal Q2 earnings likely to be marred by a soft Dental unit; Animal Health looks promising.
Henry Schein's (HSIC) Q3 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
All four of Henry Schein's (HSIC) operating segments recording year-over-year growth in Q3 encourages us.
HSIC vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. WST: Which Stock Is the Better Value Option?
Integra (IART) Q3 Earnings Meet Estimates, Revenue View Dips
by Zacks Equity Research
Integra LifeSciences' (IART) success with its channel expansion policy and Codman acquisition raise optimism on the stock.
Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is well placed to gain from the digitalization trend in the global dental market.
NuVasive (NUVA) Q3 Earnings Lag Estimates, Revenues Top Mark
by Zacks Equity Research
NuVasive (NUVA) registers balanced growth across its couple of business wings.
Chemed (CHE) Beats on Q3 Earnings, Raises 2018 Guidance
by Zacks Equity Research
The expansion in adjusted operating margin at Chemed (CHE) raises investor hopes on the stock.
Henry Schein (HSIC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Henry Schein (HSIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerner's (CERN) Q3 Earnings Match Estimates, Bookings Up Y/Y
by Zacks Equity Research
Cerner (CERN) gains from strong segmental revenues in the third quarter. Guidance for 2018 is impressive.
Merit Medical (MMSI) Tops Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) gains from solid segmental performance in Q3. Also, the company reiterated its guidance for 2018.
Stryker (SYK) Beats Q3 Earnings, Misses Sales Estimates
by Zacks Equity Research
Stryker's (SYK) Q3 results benefit from solid segmental performance. Also, the company sustained strength in International sales.
McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates
by Zacks Equity Research
McKesson's (MCK) Q2 results benefit from solid performance in the Medical-Surgical Solutions segment.
Varian (VAR) Misses Earnings, Beats Revenue Estimates in Q4
by Zacks Equity Research
Varian's (VAR) Q4 results benefit from strong growth in Oncology Systems. Also, solid guidance boosts investors' optimism.
LabCorp (LH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
LabCorp (LH) might sustain its winning streak in third-quarter 2018 after having retained the same for the past few quarters. However, reimbursement pressure remains a concern.
Can Overall Growth Drive Thermo Fisher (TMO) Q3 Earnings?
by Zacks Equity Research
Thermo Fisher's (TMO) steadily strong analytical instrument business flaunts higher global demand.
HSIC or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. MMSI: Which Stock Is the Better Value Option?
Will Boston Scientific's (BSX) Q3 Earnings Reflect Overall Gain?
by Zacks Equity Research
We are optimistic about the IC business that will help Boston Scientific (BSX) maintain impressive global growth, owing to an innovative portfolio and robust commercial teams.
Can Abbott's (ABT) Steady Overall Growth Aid Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) is consistently well-placed on a healthy growth trajectory within its Diabetes Care business for the past few quarters.